Andrew J. Barkmeier - Concepedia

Author

Andrew J. Barkmeier

Also Known As

A. Barkmeier, ANDREW J. BARKMEIER, Ala Moshiri, Andrew Barkmeier, Andrew J Barkmeier, Andrew J. Barkmeier, C. Shah, Daniel F. Martin, Hani Slahi-Had, Sangeeta Bhargava

124

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Arizona Mayo Clinic in Florida George Washington University Joslin Diabetes Center

About

Andrew J. Barkmeier is an author at Mayo Clinic specializing in medicine, ophthalmology, and diabetic retinopathy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	739
2	Diabetes	5	5	125
3	Public Health	3	3	170
4	Engineering	1	1	21
5	Geriatrics	1	1	23

Andrew J. Barkmeier

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Cultured Rat Microglial Cells Synthesize the Endocannabinoid 2-Arachidonylglycerol, Which Increases Proliferation via a CB2 Receptor-Dependent Mechanism Erica J. Carrier, Christopher S. Kearn, Andrew J. Barkmeier, Molecular Pharmacology	2004	331
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials Alex Willoughby, Gui‐Shuang Ying, Cynthia A. Toth, Ophthalmology Ocular DiseaseRetinaVitreous BodyOphthalmologyAge-related Diseases	2015	204
Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study Dean P. Hainsworth, Ionut Bebu, Lloyd Paul Aiello, Diabetes Care	2019	186
Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Jonathan Q. Purnell, Barbara H. Braffett, Bernard Zinman, Diabetes Care	2017	112
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients Ravi Parikh, Joseph S. Ross, Lindsey R. Sangaralingham, Ophthalmology Ocular DiseaseHealth PolicyOphthalmologyMedicare Advantage PatientsHealth Insurance	2016	96
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice Maya H. Maloney, Stephanie Payne, Jeph Herrin, Ophthalmology Intravitreal BevacizumabPatient SafetyRoutine Clinical PracticePharmacotherapySystemic Adverse Events	2020	69
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy Raj K. Maturi, Adam R. Glassman, Kristin Josic, JAMA	2023	53
Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Michael M. Altaweel, Ebenezer Daniel, Daniel Martín, Ophthalmology Lesions ComposedOcular DiseaseOphthalmologyExperimental OphthalmologyAge-related Diseases	2014	51
High Variation of Intravitreal Injection Rates and Medicare Anti–Vascular Endothelial Growth Factor Payments per Injection in the United States Jay C. Erie, Andrew J. Barkmeier, David O. Hodge, Ophthalmology Cardiovascular DiseaseHealth PolicyHealth EconomicsIntravitreal Injection RatesHealth Insurance	2016	51
Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice Maya H. Maloney, Stephanie R. Schilz, Jeph Herrin, Ophthalmology Diabetic RetinopathyOcular DiseaseIntravitreal Anti–vegf TherapyOphthalmologyCardiovascular Disease	2018	44

Page 1